Tyra Biosciences, Inc. (TYRA)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized (gain) loss on marketable securities available-for-sale, net | -252 | |||
| Research and development | 24,309 | |||
| General and administrative | 7,143 | |||
| Total operating expenses | 31,452 | |||
| Loss from operations | -31,452 | |||
| Interest and other income, net | 3,354 | |||
| Total other income | 3,354 | |||
| Net loss | -28,098 | |||
| Comprehensive loss | -28,350 | |||
| Net loss per share, basic | -0.47 | |||
| Net loss per share, diluted | -0.47 | |||
| Weighted average number of shares outstanding, basic | 59,550,771 | |||
| Weighted average number of shares outstanding, diluted | 59,550,771 | |||